Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 424

1.

IDegLira: combining efficacy, durability, and convenience?

Bellary S, Tahrani AA, Barnett AH.

Lancet Diabetes Endocrinol. 2019 Jun 7. pii: S2213-8587(19)30198-6. doi: 10.1016/S2213-8587(19)30198-6. [Epub ahead of print] No abstract available.

PMID:
31189518
2.

High-Density, Long-Lasting, and Multi-region Electrophysiological Recordings Using Polymer Electrode Arrays.

Chung JE, Joo HR, Fan JL, Liu DF, Barnett AH, Chen S, Geaghan-Breiner C, Karlsson MP, Karlsson M, Lee KY, Liang H, Magland JF, Pebbles JA, Tooker AC, Greengard LF, Tolosa VM, Frank LM.

Neuron. 2019 Jan 2;101(1):21-31.e5. doi: 10.1016/j.neuron.2018.11.002. Epub 2018 Nov 27.

PMID:
30502044
3.

Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.

Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.

Diabetes Obes Metab. 2018 Aug;20(8):1921-1927. doi: 10.1111/dom.13318. Epub 2018 May 3.

PMID:
29652101
4.

Once-weekly GLP-1R agonists: moving the goal posts.

Tahrani AA, Bellary S, Barnett AH.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):260-261. doi: 10.1016/S2213-8587(18)30049-4. Epub 2018 Feb 1. No abstract available.

PMID:
29397375
5.

A Fully Automated Approach to Spike Sorting.

Chung JE, Magland JF, Barnett AH, Tolosa VM, Tooker AC, Lee KY, Shah KG, Felix SH, Frank LM, Greengard LF.

Neuron. 2017 Sep 13;95(6):1381-1394.e6. doi: 10.1016/j.neuron.2017.08.030.

6.

Type 2 diabetes in adolescents and young adults.

Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):69-80. doi: 10.1016/S2213-8587(17)30186-9. Epub 2017 Aug 25. Review.

PMID:
28847479
7.

Obstructive Sleep Apnea and Retinopathy in Patients with Type 2 Diabetes. A Longitudinal Study.

Altaf QA, Dodson P, Ali A, Raymond NT, Wharton H, Fellows H, Hampshire-Bancroft R, Shah M, Shepherd E, Miah J, Barnett AH, Tahrani AA.

Am J Respir Crit Care Med. 2017 Oct 1;196(7):892-900. doi: 10.1164/rccm.201701-0175OC.

8.

Guidelines for type 2 diabetes: keeping a finger on the pulse.

Barnett AH, O'Hare P, Halcox J.

Lancet Diabetes Endocrinol. 2017 Jun;5(6):420. doi: 10.1016/S2213-8587(17)30136-5. Epub 2017 Apr 19. No abstract available.

PMID:
28433343
9.

Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy.

Owens DR, Monnier L, Barnett AH.

Diabetes Obes Metab. 2017 Oct;19(10):1339-1352. doi: 10.1111/dom.12977. Epub 2017 Jun 9. Review.

10.

Peripheral and Autonomic Neuropathy in South Asians and White Caucasians with Type 2 Diabetes Mellitus: Possible Explanations for Epidemiological Differences.

Tahrani AA, Altaf QA, Piya MK, Barnett AH.

J Diabetes Res. 2017;2017:1273789. doi: 10.1155/2017/1273789. Epub 2017 Mar 20.

11.

Prevalence and Associations of Obstructive Sleep Apnea in South Asians and White Europeans with Type 2 Diabetes: A Cross-Sectional Study.

Amin A, Ali A, Altaf QA, Piya MK, Barnett AH, Raymond NT, Tahrani AA.

J Clin Sleep Med. 2017 Apr 15;13(4):583-589. doi: 10.5664/jcsm.6548.

12.

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.

Tahrani AA, Barnett AH, Bailey CJ.

Nat Rev Endocrinol. 2016 Oct;12(10):566-92. doi: 10.1038/nrendo.2016.86. Epub 2016 Jun 24. Review.

PMID:
27339889
13.

Perceptions of diabetes control among people with type 2 diabetes treated with basal insulin in Sweden, Switzerland, and the United Kingdom.

Brod M, Pfeiffer KM, Barnett AH, Berntorp K, Vilsbøll T, Weissenberger B.

Curr Med Res Opin. 2016 Oct;32(10):1653-1661. doi: 10.1080/03007995.2016.1198311. Epub 2016 Jul 11.

PMID:
27263866
14.

Health and population effects of rare gene knockouts in adult humans with related parents.

Narasimhan VM, Hunt KA, Mason D, Baker CL, Karczewski KJ, Barnes MR, Barnett AH, Bates C, Bellary S, Bockett NA, Giorda K, Griffiths CJ, Hemingway H, Jia Z, Kelly MA, Khawaja HA, Lek M, McCarthy S, McEachan R, O'Donnell-Luria A, Paigen K, Parisinos CA, Sheridan E, Southgate L, Tee L, Thomas M, Xue Y, Schnall-Levin M, Petkov PM, Tyler-Smith C, Maher ER, Trembath RC, MacArthur DG, Wright J, Durbin R, van Heel DA.

Science. 2016 Apr 22;352(6284):474-7. doi: 10.1126/science.aac8624. Epub 2016 Mar 3.

15.

Validation of neural spike sorting algorithms without ground-truth information.

Barnett AH, Magland JF, Greengard LF.

J Neurosci Methods. 2016 May 1;264:65-77. doi: 10.1016/j.jneumeth.2016.02.022. Epub 2016 Feb 28.

PMID:
26930629
16.

Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database.

Watson L, Das R, Farquhar R, Langerman H, Barnett AH.

Curr Med Res Opin. 2016 Sep;32(9):1465-75. doi: 10.1185/03007995.2016.1157462. Epub 2016 Mar 23.

PMID:
26907851
17.

Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom.

Brod M, Pfeiffer KM, Barnett AH, Berntorp K, Vilsbøll T, Weissenberger B.

Curr Med Res Opin. 2016 Jun;32(6):981-9. doi: 10.1185/03007995.2016.1150821. Epub 2016 Mar 7.

PMID:
26849483
18.

Future glucose-lowering drugs for type 2 diabetes.

Bailey CJ, Tahrani AA, Barnett AH.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):350-9. doi: 10.1016/S2213-8587(15)00462-3. Epub 2016 Jan 23. Review.

PMID:
26809680
19.

Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.

Barnett AH, Charbonnel B, Moses RG, Kalra S.

Curr Med Res Opin. 2015;31(10):1919-31. doi: 10.1185/03007995.2015.1081589. Epub 2015 Sep 11. Review.

PMID:
26361231
20.

NICE guidelines for Type 2 diabetes: revised but still not fit for purpose.

O'Hare JP, Hanif W, Millar-Jones D, Bain S, Hicks D, Leslie RD, Barnett AH.

Diabet Med. 2015 Nov;32(11):1398-403. doi: 10.1111/dme.12952. Epub 2015 Sep 23. No abstract available.

PMID:
26331592
21.

The revised NICE draft guideline for type 2 diabetes: still a long way to go.

O'Hare JP, Millar-Jones D, Hanif W, Hicks D, Leslie RD, Bain SC, Barnett AH.

Lancet Diabetes Endocrinol. 2015 Sep;3(9):679-80. doi: 10.1016/S2213-8587(15)00288-0. Epub 2015 Aug 4. No abstract available.

PMID:
26254116
22.

In defence of NICE draft type 2 diabetes guidelines--Author's reply.

Barnett AH.

Lancet Diabetes Endocrinol. 2015 Jun;3(6):406-407. doi: 10.1016/S2213-8587(15)00132-1. No abstract available.

PMID:
26003754
23.

Robust fast direct integral equation solver for quasi-periodic scattering problems with a large number of layers.

Cho MH, Barnett AH.

Opt Express. 2015 Jan 26;23(2):1775-99. doi: 10.1364/OE.23.001775.

PMID:
25835933
24.

NICE draft type 2 diabetes guidelines: a cause for concern.

Barnett AH.

Lancet Diabetes Endocrinol. 2015 Jun;3(6):403-405. doi: 10.1016/S2213-8587(15)00053-4. Epub 2015 Mar 13. No abstract available.

PMID:
25772585
25.

Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.

Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ.

Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684. No abstract available.

PMID:
25614693
26.

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.

Barnett AH.

Expert Opin Drug Saf. 2015 Jan;14(1):149-59. doi: 10.1517/14740338.2014.971008. Epub 2014 Oct 29. Review.

PMID:
25351273
27.

Novel therapeutics for type 2 diabetes: insulin resistance.

Altaf QA, Barnett AH, Tahrani AA.

Diabetes Obes Metab. 2015 Apr;17(4):319-34. doi: 10.1111/dom.12400. Epub 2014 Nov 12. Review.

PMID:
25308775
28.

Empagliflozin for the treatment of type 2 diabetes.

Jahagirdar V, Barnett AH.

Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. Review.

PMID:
25301180
29.

What factors influence concordance with medications? Findings from the U.K. Asian Diabetes study.

Lloyd CE, Mughal S, Roy T, Raymond NT, O'Hare JP, Barnett AH, Bellary S.

Diabet Med. 2014 Dec;31(12):1600-9. doi: 10.1111/dme.12554. Epub 2014 Aug 28.

PMID:
25073479
30.

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.

Schernthaner G, Barnett AH, Patel S, Hehnke U, von Eynatten M, Woerle HJ.

Diabetes Obes Metab. 2014 Nov;16(11):1078-86. doi: 10.1111/dom.12321. Epub 2014 Jul 3.

PMID:
24865132
31.

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators.

Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24.

PMID:
24795251
32.

Elevated serum free light chains predict cardiovascular events in type 2 diabetes.

Bellary S, Faint JM, Assi LK, Hutchison CA, Harding SJ, Raymond NT, Barnett AH.

Diabetes Care. 2014 Jul;37(7):2028-30. doi: 10.2337/dc13-2227. Epub 2014 Apr 17.

PMID:
24742658
33.

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group.

Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-97. doi: 10.1016/S2213-8587(13)70214-6. Epub 2014 Feb 6. Erratum in: Lancet Diabetes Endocrinol. 2014 Mar;2(3):e5.

PMID:
24703047
34.

SGLT inhibitors in management of diabetes.

Tahrani AA, Barnett AH, Bailey CJ.

Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51. doi: 10.1016/S2213-8587(13)70050-0. Epub 2013 Aug 13. Review. Erratum in: Lancet Diabetes Endocrinol. 2015 Apr;3(4):e3.

PMID:
24622320
36.

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility.

DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES) Consortium, Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J, Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, James A, Jia W, Jöckel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukaanniemi KM, Kelly AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, Kong A, Korpi-Hyövälti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Mägi R, Männisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Mühleisen TW, Müller-Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, Nilsson PM, Njølstad I, Nöthen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees SD, Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, Scott LJ, Scott RA, Segrè AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu XO, Shuldiner AR, Sigurđsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, Small KS, So WY, Stančáková A, Stefansson K, Steinbach G, Steinthorsdottir V, Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvänen AC, Takayanagi R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, McCarthy MI, Morris AP.

Nat Genet. 2014 Mar;46(3):234-44. doi: 10.1038/ng.2897. Epub 2014 Feb 9.

37.

A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.

DeVries JH, Meneghini L, Barnett AH, Reid T, Dain MP, Landgraf W, Vlajnic A, Traylor L, Bergenstal RM.

Eur Endocrinol. 2014 Feb;10(1):23-30. doi: 10.17925/EE.2014.10.01.23. Epub 2014 Feb 28.

38.

Linagliptin for elderly patients with type 2 diabetes - Authors' reply.

Barnett AH, von Eynatten M, Patel S, Woerle HJ.

Lancet. 2014 Jan 25;383(9914):307-8. doi: 10.1016/S0140-6736(14)60104-5. No abstract available.

PMID:
24461123
39.

Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome.

Patel A, Rees SD, Kelly MA, Bain SC, Barnett AH, Prasher A, Arshad H, Prasher VP.

BMC Res Notes. 2014 Jan 17;7:42. doi: 10.1186/1756-0500-7-42.

40.

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH.

Diabetes Obes Metab. 2014 May;16(5):433-42. doi: 10.1111/dom.12239. Epub 2013 Dec 16. Review.

PMID:
24237939
41.

The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease.

Burmeister A, Assi LK, Ferro CJ, Hughes RG, Barnett AH, Bellary S, Cockwell P, Pratt G, Hutchison CA.

Int J Lab Hematol. 2014 Aug;36(4):415-24. doi: 10.1111/ijlh.12159. Epub 2013 Nov 5.

PMID:
24188493
42.

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.

McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, von Eynatten M, Woerle HJ.

Diab Vasc Dis Res. 2014 Jan;11(1):34-40. doi: 10.1177/1479164113507068. Epub 2013 Oct 29.

PMID:
24169807
43.

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.

Barnett AH.

Postgrad Med. 2013 Sep;125(5):92-100. doi: 10.3810/pgm.2013.09.2698. Review.

PMID:
24113667
44.

Obstructive sleep apnea and diabetic nephropathy: a cohort study.

Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Altaf QA, Piya MK, Barnett AH, Stevens MJ.

Diabetes Care. 2013 Nov;36(11):3718-25. doi: 10.2337/dc13-0450. Epub 2013 Sep 23.

45.

Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).

Mathieu C, Barnett AH, Brath H, Conget I, de Castro JJ, Göke R, Márquez Rodriguez E, Nilsson PM, Pagkalos E, Penfornis A, Schaper NC, Wangnoo SK, Kothny W, Bader G.

Int J Clin Pract. 2013 Oct;67(10):947-56. doi: 10.1111/ijcp.12252. Epub 2013 Aug 21.

46.

High frequency of autoantibodies in patients with long duration type 1 diabetes.

Richardson CC, Dromey JA, McLaughlin KA, Morgan D, Bodansky HJ, Feltbower RG, Barnett AH, Gill GV, Bain SC, Christie MR.

Diabetologia. 2013 Aug 20. [Epub ahead of print] No abstract available.

PMID:
23959572
47.

Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents.

Barnett AH, Brice R, Hanif W, James J, Langerman H.

Curr Med Res Opin. 2013 Nov;29(11):1503-13. doi: 10.1185/03007995.2013.834250. Epub 2013 Sep 6. Review.

PMID:
23952328
48.

Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.

Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N.

Clin Drug Investig. 2013 Oct;33(10):707-17. doi: 10.1007/s40261-013-0107-8.

PMID:
23949898
49.

Risk of breast cancer by individual insulin use: an international multicenter study.

Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L; ISICA Group.

Diabetes Care. 2014;37(1):134-43. doi: 10.2337/dc13-0695. Epub 2013 Aug 15.

PMID:
23949559
50.

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.

Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.

Lancet. 2013 Oct 26;382(9902):1413-23. doi: 10.1016/S0140-6736(13)61500-7. Epub 2013 Aug 13.

PMID:
23948125

Supplemental Content

Loading ...
Support Center